Indications
ZENAPAX® (daclizumab) is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants. It is used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.5
Safety
Information
Reference:
5ZENAPAX® [product information]. Nutley, NJ: Roche Laboratories Inc.; September 2005.